AWA
GYRE icon

Arete Wealth Advisors’s Gyre Therapeutics GYRE Stock Holding History

Arete Wealth Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-723
Closed -$5.23K – 757
2023
Q3 		$5.23K Buy
+723
New +$4.84K ﹤0.01% 504
2023
Q2 		– Sell
-690
Closed -$2K – 704
2023
Q1 		$2K Buy
+690
New +$2.62K ﹤0.01% 654

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Arete Wealth Advisors's GYRE Position: Q4 2023 in Review

Arete Wealth Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 723 shares — an estimated $5.23K sold.

Arete Wealth Advisors first reported a position in GYRE in Q1 2023 and held it in 2 quarters. The position peaked at $5.23K in Q3 2023. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Arete Wealth Advisors reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Arete Wealth Advisors sold 723 Gyre Therapeutics shares in Q4 2023, an estimated $5.23K.
  • Arete Wealth Advisors first reported a position in Gyre Therapeutics in Q1 2023 and held it in 2 quarters.
  • Arete Wealth Advisors's Gyre Therapeutics position peaked at $5.23K in Q3 2023.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Arete Wealth Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.